Adamantane Memantine Derivatives Peripheral NMDA Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pulmonary arterial hypertension (PAH) are limited by severe side effects and lack of effective anti-remodeling strategies, with existing NMDA receptor blockers unable to target peripheral receptors without causing central nervous system side effects, necessitating the development of novel peripheral NMDA receptor antagonists that do not cross the blood-brain barrier.
Innovation Solution
Development of cationic compounds with specific chemical modifications to memantine and adamantine derivatives that selectively block peripheral NMDA receptors without penetrating the central nervous system, achieved through modifications that reduce brain penetration while maintaining effective peripheral activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing NMDA receptor blockers are used to treat pulmonary hypertension, then peripheral NMDA receptors can be blocked, but central nervous system side effects occur due to blood-brain barrier penetration
Solution Approach 1:
The patent applies local quality by creating compounds with asymmetric substitution patterns on the adamantane ring (specifically at positions 1 and 3), where different substituents are placed to achieve selective peripheral activity. The compounds feature a basic nitrogen atom in a specific spatial arrangement that enables selective interaction with peripheral NMDA receptors while preventing CNS penetration, thus resolving the contradiction between peripheral efficacy and CNS side effects
Solution Approach 2:
The patent uses the adamantane derivative structure as an intermediary molecule that carries the NMDA receptor blocking function to peripheral tissues while its specific chemical properties (basic nitrogen, asymmetric substitution) prevent it from acting as a mediator for CNS penetration. This intermediary structure selectively delivers the therapeutic effect to peripheral NMDA receptors without crossing into the central nervous system
2Stress or pressure
If current PAH therapies are used to decrease pulmonary vascular resistance, then pulmonary vasodilation is achieved, but anti-remodeling effects are insufficient
Solution Approach 1:
The patent extracts the NMDA receptor blocking function from the complex pathophysiology of PAH and isolates it as a specific therapeutic target. By focusing on blocking peripheral NMDA receptors involved in vascular remodeling, the invention separates this specific mechanism from the overall disease process, allowing targeted intervention that addresses remodeling without requiring broad-spectrum effects of current therapies
Solution Approach 2:
The patent changes the therapeutic parameter from general vasodilation to specific NMDA receptor antagonism. The compounds of formula (I) are designed to block NMDA receptors with specific kinetic properties, changing the approach from modifying vascular tone to preventing receptor-mediated remodeling processes, thereby addressing the insufficiency of anti-remodeling effects in current therapies
3Reliability
If NMDA receptor blockers are designed to cross the blood-brain barrier for CNS indications, then central NMDA receptors are blocked, but peripheral selectivity is lost
Solution Approach 1:
The patent inverts the conventional approach by designing NMDA receptor blockers that specifically avoid crossing the blood-brain barrier. Instead of optimizing for CNS penetration, the compounds are structurally designed with features (basic nitrogen, specific substitution pattern) that prevent BBB crossing while maintaining peripheral NMDA receptor affinity, thus achieving peripheral selectivity through inverted design logic
Data Source
Figure 1~2
AI summary
The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.